Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Gastric Cancer

Volumn 18, Issue 4, 2015, Pages 824-832

  Satoh, Taroh ^a   Lee, Kyung Hee ^b   Rha, Sun Young ^c   Sasaki, Yasutsuna ^d   Park, Se Hoon ^e   Komatsu, Yoshito ^f   Yasui, Hirofumi ^g   Kim, Tae You ^h   Yamaguchi, Kensei ⁱ   Fuse, Nozomu ^j   Yamada, Yasuhide ^k   Ura, Takashi ^l   Kim, Si Young ^m   Munakata, Masaki ⁿ   Saitoh, Soh ^o   Nishio, Kazuto ^p   Morita, Satoshi ^q   Yamamoto, Eriko ^r   Zhang, Qingwei ^r   Kim, Jung mi ^s   Kim, Yeul Hong ^t   Sakata, Yuh ⁿ   more..

^a KINKI UNIVERSITY   (Japan)

^b Young Nam University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e Samsung Medical Center   (South Korea)

^f HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h Seoul National University Hospital   (South Korea)

ⁱ SAITAMA CANCER CENTER   (Japan)

^j NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^k NATIONAL CANCER CENTER HOSPITAL   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m Kyung Hee University College of Medicine   (South Korea)

ⁿ Department of Internal Medicine   (Japan)

^o AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^p KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q YOKOHAMA CITY UNIVERSITY   (Japan)

^r DAIICHI SANKYO CO   (Japan)

^s R and D Center   (South Korea)

^t Korea University College of Medicine   (South Korea)

more..

Author keywords

Advanced gastric cancer; Anti EGFR; Irinotecan; Nimotuzumab; Second line therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HEMOGLOBIN; IRINOTECAN; IRINOTECAN PLUS NIMOTUZUMAB; NIMOTUZUMAB; UNCLASSIFIED DRUG; CAMPTOTHECIN; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; INFUSION RELATED REACTION; INOPERABLE CANCER; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN TOXICITY; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ADULT; AGED; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PROCEDURES; SALVAGE THERAPY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SALVAGE THERAPY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84942115572     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0420-9     Document Type: Article

References (31)

1. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer (Phila). 1993;72:37–41.
2. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
8. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306–14.
9. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513–8.
10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
11. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.
12. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology (Oxf). 2008;52:738–46.
13. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of human epidermal growth factor receptor EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18(21):5992–6000.
14. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer. 2001;101:567–75.
15. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69:5851–9.
16. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11:373–82.
17. Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003;26:139–48.
18. Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, et al. A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72:1063–71.
19. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646–54.
20. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5:375–9.
21. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer (Phila). 2001;92:1331–46.
22. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–55.
23. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol. 2004;34:8–13.
24. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2006;9:14–8.
25. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007;27:2667–71.
26. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–9.
27. Waddell TS, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–9.
28. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer. 2008;98:749–55.
29. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9(5):343–9.
30. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, et al. BRAF and KRAS mutations in stomach cancer. Oncogene. 2003;22:6942–5.
31. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology (Oxf). 2008;52(6):738–46.